Physician profile
Daljit Singh
NPI 1952364044
$35,329.43
in general payments reported to CMS, 2019-2025
65 companies · $4,301 in 2025
The $4,301 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,093 · 2020: $4,872 · 2021: $6,130 · 2022: $5,198 · 2023: $4,524 · 2024: $5,212 · 2025: $4,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,024.76 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,228.50 | 2019-2025 | Wegovy, Saxenda, Rybelsus |
| Janssen Pharmaceuticals, INC | $3,676.21 | 2019-2025 | Xarelto, Spravato |
| Abbvie INC. | $3,013.38 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $2,890.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $2,849.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,490.20 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $2,459.44 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $2,160.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $1,184.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,079.14 | 2019-2025 | Verquvo, Belsomra, Steglujan |
| Avanir Pharmaceuticals, INC. | $1,053.41 | 2019-2022 | |
| Astellas Pharma US INC | $664.06 | 2019-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $605.65 | 2019-2025 | Injectafer |
| Pfizer INC. | $582.91 | 2019-2025 | |
| Amarin Pharma, INC. | $582.69 | 2019-2021 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.